Friday, April 3, 2009

Cell Therapeutics Dodges Delisting

Seattle-based Cell Therapeutics, which is developing cancer treatment drugs, said Friday morning that the firm has received a notice from the NASDAQ, saying that it is in full compliance with requirements for continued listing on the NASDAQ Capital market. The firm had been warned in September and October that it did not meet requirements for listing on the NASDAQ Global Market, which resulted in a transfer of the firm's listing to the less stringent NASDAQ Capital Market. The company had until April 6th to meet the requirements, which requires a minimum $35M market value in firms listed on the exchange.